A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells

Cell Reports

Volumn 19, Issue 7, 2017, Pages 1479-1493

  Ersing, Ina ^a,b   Nobre, Luis ^c   Wang, Liang Wei ^a,d   Soday, Lior ^c   Ma, Yijie ^a   Paulo, Joao A ^d   Narita, Yohei ^a,d   Ashbaugh, Camille W ^a   Jiang, Chang ^a   Grayson, Nicholas E ^e   Kieff, Elliott ^a,d   Gygi, Steven P ^d   Weekes, Michael P ^c   Gewurz, Benjamin E ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

B cell receptor; complement; Epstein Barr virus; herpesvirus; host pathogen interaction; immune evasion; lytic replication; quantitative proteomics; tandem mass tag; viral evasion

Indexed keywords

B LYMPHOCYTE RECEPTOR; MEMBRANE PROTEIN; PROTEASOME; VIRAL PROTEIN; COMPLEMENT; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA CELL LINE; CELL CYCLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS INFECTION; ENZYME DEGRADATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; IMMUNE EVASION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; UPREGULATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; CELL MEMBRANE; DOWN REGULATION; METABOLISM; PHYSIOLOGY; PROCEDURES; PROTEIN DEGRADATION; TIME FACTOR; VIROLOGY;

B-LYMPHOCYTES; CELL CYCLE; CELL MEMBRANE; COMPLEMENT SYSTEM PROTEINS; DOWN-REGULATION; HERPESVIRUS 4, HUMAN; HUMANS; PROTEOLYSIS; PROTEOMICS; RECEPTORS, ANTIGEN, B-CELL; TIME FACTORS; TRANSCRIPTION FACTORS; UP-REGULATION; VIRUS REPLICATION;

EID: 85019256983     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.04.062     Document Type: Article

References (72)

1. Adamson, A.L., Le, B.T., Siedenburg, B.D., Inhibition of mTORC1 inhibits lytic replication of Epstein-Barr virus in a cell-type specific manner. Virol. J., 11, 2014, 110.
2. Arvey, A., Tempera, I., Tsai, K., Chen, H.S., Tikhmyanova, N., Klichinsky, M., Leslie, C., Lieberman, P.M., An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12 (2012), 233–245.
3. Aubry, V., Mure, F., Mariamé, B., Deschamps, T., Wyrwicz, L.S., Manet, E., Gruffat, H., Epstein-Barr virus late gene transcription depends on the assembly of a virus-specific preinitiation complex. J. Virol. 88 (2014), 12825–12838.
4. Balachandran, N., Pittari, J., Hutt-Fletcher, L.M., Detection by monoclonal antibodies of an early membrane protein induced by Epstein-Barr virus. J. Virol. 60 (1986), 369–375.
5. Blaszczyk, K., Nowicka, H., Kostyrko, K., Antonczyk, A., Wesoly, J., Bluyssen, H.A., The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 29 (2016), 71–81.
6. Calderwood, M.A., Holthaus, A.M., Johannsen, E., The Epstein-Barr virus LF2 protein inhibits viral replication. J. Virol. 82 (2008), 8509–8519.
7. Cen, O., Longnecker, R., Latent Membrane Protein 2 (LMP2). Curr. Top. Microbiol. Immunol. 391 (2015), 151–180.
8. Chesnokova, L.S., Valencia, S.M., Hutt-Fletcher, L.M., The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection. Virology 494 (2016), 23–28.
9. Chien, Y.C., Chen, J.Y., Liu, M.Y., Yang, H.I., Hsu, M.M., Chen, C.J., Yang, C.S., Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345 (2001), 1877–1882.
10. Chiu, Y.F., Sugden, B., Epstein-Barr virus: The path from latent to productive infection. Annu. Rev. Virol. 3 (2016), 359–372.
11. Chiu, Y.F., Sugden, A.U., Sugden, B., Epstein-Barr viral productive amplification reprograms nuclear architecture, DNA replication, and histone deposition. Cell Host Microbe 14 (2013), 607–618.
12. Cohen, J.I., Fauci, A.S., Varmus, H., Nabel, G.J., Epstein-Barr virus: An important vaccine target for cancer prevention. Sci. Transl. Med., 3, 2011, 107fs7.
13. Colby, B.M., Shaw, J.E., Elion, G.B., Pagano, J.S., Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J. Virol. 34 (1980), 560–568.
14. Concha, M., Wang, X., Cao, S., Baddoo, M., Fewell, C., Lin, Z., Hulme, W., Hedges, D., McBride, J., Flemington, E.K., Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-seq. J. Virol. 86 (2012), 1458–1467.
15. Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26 (2008), 1367–1372.
16. Djavadian, R., Chiu, Y.F., Johannsen, E., An Epstein-Barr virus-encoded protein complex requires an origin of lytic replication in cis to mediate late gene transcription. PLoS Pathog., 12, 2016, e1005718.
17. Dorrello, N.V., Peschiaroli, A., Guardavaccaro, D., Colburn, N.H., Sherman, N.E., Pagano, M., S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314 (2006), 467–471.
18. Duan, S., Cermak, L., Pagan, J.K., Rossi, M., Martinengo, C., di Celle, P.F., Chapuy, B., Shipp, M., Chiarle, R., Pagano, M., FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481 (2012), 90–93.
19. Feighny, R.J., Henry, B.E. 2nd, Pagano, J.S., Epstein-Barr virus polypeptides: Effect of inhibition of viral DNA replication on their synthesis. J. Virol. 37 (1981), 61–71.
20. Gore, M., Hutt-Fletcher, L.M., The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein. Virology 383 (2009), 162–167.
21. Grayson, S., Johnson-Winegar, A.G., Wintroub, B.U., Isseroff, R.R., Epstein, E.H. Jr., Elias, P.M., Lamellar body-enriched fractions from neonatal mice: Preparative techniques and partial characterization. J. Invest. Dermatol. 85 (1985), 289–294.
22. Hammerschmidt, W., Sugden, B., Replication of Epstein-Barr viral DNA. Cold Spring Harb. Perspect. Biol., 5, 2013, a013029.
23. Havens, C.G., Walter, J.C., Mechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligase. Genes Dev. 25 (2011), 1568–1582.
24. Hess, C., Kemper, C., Complement-mediated regulation of metabolism and basic cellular processes. Immunity 45 (2016), 240–254.
25. Hibi, T., Dosch, H.M., Limiting dilution analysis of the B cell compartment in human bone marrow. Eur. J. Immunol. 16 (1986), 139–145.
26. Hook, L.M., Friedman, H.M., Subversion of innate and adaptive immunity: Immune evasion from antibody and complement. Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., (eds.) Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, 2007, Cambridge, 1137–1150.
27. Huang, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
28. Hutt-Fletcher, L.M., EBV glycoproteins: Where are we now?. Future Virol. 10 (2015), 1155–1162.
29. Huttlin, E.L., Jedrychowski, M.P., Elias, J.E., Goswami, T., Rad, R., Beausoleil, S.A., Villén, J., Haas, W., Sowa, M.E., Gygi, S.P., A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143 (2010), 1174–1189.
30. Kenney, S.C., Reactivation and lytic replication of EBV. Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., (eds.) Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, 2007, Cambridge.
31. Kenney, S.C., Mertz, J.E., Regulation of the latent-lytic switch in Epstein-Barr virus. Semin. Cancer Biol. 26 (2014), 60–68.
32. Kieff, E., Rickinson, A., Epstein-Barr virus and its replication. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, 2007, Lippincott, 2603–2654.
33. Klein, G., Sugden, B., Leibold, W., Menezes, J., Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV. Intervirology 3 (1974), 232–244.
34. Koganti, S., Clark, C., Zhi, J., Li, X., Chen, E.I., Chakrabortty, S., Hill, E.R., Bhaduri-McIntosh, S., Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr virus lytic activation in B lymphocytes. J. Virol. 89 (2015), 5002–5011.
35. Kolev, M., Dimeloe, S., Le Friec, G., Navarini, A., Arbore, G., Povoleri, G.A., Fischer, M., Belle, R., Loeliger, J., Develioglu, L., et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42 (2015), 1033–1047.
36. Laichalk, L.L., Thorley-Lawson, D.A., Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79 (2005), 1296–1307.
37. Lalli, P.N., Strainic, M.G., Yang, M., Lin, F., Medof, M.E., Heeger, P.S., Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112 (2008), 1759–1766.
38. Lee, M.S., Jones, T., Song, D.Y., Jang, J.H., Jung, J.U., Gao, S.J., Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection. PLoS Pathog., 10, 2014, e1004412.
39. Lin, J.C., Raab-Traub, N., Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells. J. Virol. 61 (1987), 1985–1991.
40. Ma, S.D., Hegde, S., Young, K.H., Sullivan, R., Rajesh, D., Zhou, Y., Jankowska-Gan, E., Burlingham, W.J., Sun, X., Gulley, M.L., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 85 (2011), 165–177.
41. Matheson, C.J., Backos, D.S., Reigan, P., Targeting WEE1 Kinase in Cancer. Trends Pharmacol. Sci. 37 (2016), 872–881.
42. McKenzie, J., El-Guindy, A., Epstein-Barr virus lytic cycle reactivation. Curr. Top. Microbiol. Immunol. 391 (2015), 237–261.
43. Miller, G., Robinson, J., Heston, L., Lipman, M., Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc. Natl. Acad. Sci. USA 71 (1974), 4006–4010.
44. Mold, C., Bradt, B.M., Nemerow, G.R., Cooper, N.R., Epstein-Barr virus regulates activation and processing of the third component of complement. J. Exp. Med. 168 (1988), 949–969.
45. Moody, C.A., Scott, R.S., Amirghahari, N., Nathan, C.O., Young, L.S., Dawson, C.W., Sixbey, J.W., Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J. Virol. 79 (2005), 5499–5506.
46. Nemerow, G.R., Houghten, R.A., Moore, M.D., Cooper, N.R., Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56 (1989), 369–377.
47. Nutt, S.L., Hodgkin, P.D., Tarlinton, D.M., Corcoran, L.M., The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15 (2015), 160–171.
48. Paladino, P., Marcon, E., Greenblatt, J., Frappier, L., Identification of herpesvirus proteins that contribute to G1/S arrest. J. Virol. 88 (2014), 4480–4492.
49. Palser, A.L., Grayson, N.E., White, R.E., Corton, C., Correia, S., Ba Abdullah, M.M., Watson, S.J., Cotten, M., Arrand, J.R., Murray, P.G., et al. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. J. Virol. 89 (2015), 5222–5237.
50. Powles, T., Robinson, D., Stebbing, J., Shamash, J., Nelson, M., Gazzard, B., Mandelia, S., Møller, H., Bower, M., Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol. 27 (2009), 884–890.
51. Quinn, L.L., Williams, L.R., White, C., Forrest, C., Zuo, J., Rowe, M., The missing link in Epstein-Barr virus immune evasion: The BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II. J. Virol. 90 (2015), 356–367.
52. Rathinam, V.A., Jiang, Z., Waggoner, S.N., Sharma, S., Cole, L.E., Waggoner, L., Vanaja, S.K., Monks, B.G., Ganesan, S., Latz, E., et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11 (2010), 395–402.
53. Rowe, M., Glaunsinger, B., van Leeuwen, D., Zuo, J., Sweetman, D., Ganem, D., Middeldorp, J., Wiertz, E.J., Ressing, M.E., Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl. Acad. Sci. USA 104 (2007), 3366–3371.
54. Schoggins, J.W., Wilson, S.J., Panis, M., Murphy, M.Y., Jones, C.T., Bieniasz, P., Rice, C.M., A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 (2011), 481–485.
55. Schreiner, S., Wodrich, H., Virion factors that target Daxx to overcome intrinsic immunity. J. Virol. 87 (2013), 10412–10422.
56. Skalsky, R.L., Cullen, B.R., EBV noncoding RNAs. Curr. Top. Microbiol. Immunol. 391 (2015), 181–217.
57. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
58. Takada, K., Ono, Y., Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63 (1989), 445–449.
59. Taniguchi, T., Ogasawara, K., Takaoka, A., Tanaka, N., IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19 (2001), 623–655.
60. Thorley-Lawson, D.A., EBV persistence—introducing the virus. Curr. Top. Microbiol. Immunol. 390 (2015), 151–209.
61. Timms, R.T., Duncan, L.M., Tchasovnikarova, I.A., Antrobus, R., Smith, D.L., Dougan, G., Weekes, M.P., Lehner, P.J., Haploid genetic screens identify an essential role for PLP2 in the downregulation of novel plasma membrane targets by viral E3 ubiquitin ligases. PLoS Pathog., 9, 2013, e1003772.
62. Traylen, C., Ramasubramanyan, S., Zuo, J., Rowe, M., Almohammad, R., Heesom, K., Sweet, S.M., Matthews, D.A., Sinclair, A.J., Identification of Epstein-Barr virus replication proteins in Burkitt's lymphoma cells. Pathogens 4 (2015), 739–751.
63. Tsai, M.H., Raykova, A., Klinke, O., Bernhardt, K., Gärtner, K., Leung, C.S., Geletneky, K., Sertel, S., Münz, C., Feederle, R., Delecluse, H.J., Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep. 5 (2013), 458–470.
64. Tugizov, S.M., Herrera, R., Palefsky, J.M., Epstein-Barr virus transcytosis through polarized oral epithelial cells. J. Virol. 87 (2013), 8179–8194.
65. Verma, D., Ling, C., Johannsen, E., Nagaraja, T., Swaminathan, S., Negative autoregulation of Epstein-Barr virus (EBV) replicative gene expression by EBV SM protein. J. Virol. 83 (2009), 8041–8050.
66. Vizcaíno, J.A., Csordas, A., del-Toro, N., Dianes, J.A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y., Reisinger, F., Ternent, T., et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44:D1 (2016), D447–D456.
67. Weekes, M.P., Tomasec, P., Huttlin, E.L., Fielding, C.A., Nusinow, D., Stanton, R.J., Wang, E.C., Aicheler, R., Murrell, I., Wilkinson, G.W., et al. Quantitative temporal viromics: An approach to investigate host-pathogen interaction. Cell 157 (2014), 1460–1472.
68. Williams, S.A., Maecker, H.L., French, D.M., Liu, J., Gregg, A., Silverstein, L.B., Cao, T.C., Carano, R.A., Dixit, V.M., USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 146 (2011), 918–930.
69. Williams, L.R., Quinn, L.L., Rowe, M., Zuo, J., Induction of the lytic cycle sensitizes epstein-barr virus-infected B cells to NK cell killing that is counteracted by virus-mediated NK cell evasion mechanisms in the late lytic cycle. J. Virol. 90 (2015), 947–958.
70. Wiśniewski, J.R., Hein, M.Y., Cox, J., Mann, M., A “proteomic ruler” for protein copy number and concentration estimation without spike-in standards. Mol. Cell. Proteomics 13 (2014), 3497–3506.
71. Yang, H.S., Jansen, A.P., Komar, A.A., Zheng, X., Merrick, W.C., Costes, S., Lockett, S.J., Sonenberg, N., Colburn, N.H., The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 23 (2003), 26–37.
72. Yuan, J., Cahir-McFarland, E., Zhao, B., Kieff, E., Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 80 (2006), 2548–2565.